DSP Mutual Fund decreased its stake in Alembic Pharmaceuticals from 4.23% to 3.86%, selling 730,133 shares. The value of shares sold is ₹60.25 Cr at a price of ₹825.10 apiece.
A pharmaceutical company engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients for domestic and international markets. Alembic Pharma operates three dedicated research and development centers alongside five manufacturing facilities to support its operations across multiple therapeutic areas. The company focuses on producing generic and specialized pharmaceutical products while maintaining vertically integrated operations.
Standalone AMC after DSP Group acquired full ownership from BlackRock in 2018. Manages over Rs 1.9 lakh crore. Known for equity funds with a clear process-first culture and minimal star manager dependency. CEO Kalpen Parekh is widely respected for transparent investor communication. DSP Small Cap Fund and DSP Midcap Fund are flagship offerings.
